Trial reportAmerican journal of respiratory and critical care medicine2023
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
Abstract readClinical Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence.American journal of epidemiology · 2026Observational
- Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation.medRxiv : the preprint server for health sciences · 2026Article
- Design and Implementation of Observational Studies Emulating a Target Trial.JAMA network open · 2026Article
- Interim Effectiveness and Safety of Prolonged Bedaquiline Use in Comparison to Standard 24-Week Treatment for MDR-TB: A Multicenter Cohort Study in China.Infection and drug resistance · 2026Article
- Real-world effectiveness and safety of prolonged bedaquiline course in the treatment of drug-resistant tuberculosis-a multi-center retrospective cohort study in a country with a high burden of drug-resistant tuberculosis.Microbiology spectrum · 2025Article
- Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TB.IJTLD open · 2025Article
- Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.Microorganisms · 2025Review
- Update in tuberculosis treatment: a scoping review of current practices.Breathe (Sheffield, England) · 2025Review
- Whole-genome sequencing and machine learning reveal key drivers of delayed sputum conversion in rifampicin-resistant tuberculosis.Frontiers in cellular and infection microbiology · 2025Article
- Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Neglected Populations Not to Be Forgotten: Tackling Antimicrobial Resistance in Neonatal Infections.Antibiotics (Basel, Switzerland) · 2023Article
- "Weighting" the Evidence: How Much Bedaquiline Is Enough?American journal of respiratory and critical care medicine · 2023Article
- Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.PLOS global public health · 2023Article
Corrections and comments
- Commented on by
Authors and funding
28 authors.
Letizia TrevisiDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.
Miguel A HernánCAUSALab, Departments of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
Carole D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.
Uzma KhanInteractive Research and Development Global, Singapore, Singapore.
Kwonjune J SeungDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.
Michael L RichDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.
Mathieu BastardField Epidemiology Department, Epicentre, Paris, France.
Helena HuergaField Epidemiology Department, Epicentre, Paris, France.
Nara MelikyanField Epidemiology Department, Epicentre, Paris, France.
Sidney A AtwoodDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts.
Zaza AvalianiNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Felix LlanosUnidad de Tuberculosis, Hospital Nacional Dos de Mayo, Lima, Peru.
Mohammad Manzur-Ul-AlamInteractive Research and Development, Dhaka, Bangladesh.
Khin ZarliMédecins sans Frontières, Yangon, Myanmar.
Amsalu Bekele BinegdieDepartment of Internal Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Sana AdnanIndus Hospital and Health Network, Karachi, Pakistan.
Arusyak MelikyanMédecins sans Frontières, Yerevan, Armenia.
Alain GelinZanmi Lasante, Port-au-Prince, Haiti.
Afshan K IsaniNational Core Research Group, Stop TB Partnership, Islamabad, Pakistan.
Dmitry VetushkoRepublican Scientific and Practical Centre of Pulmonology and Tuberculosis, Minsk, Belarus.
Zhenisgul DaugarinaAstana City Center of Phthisiopulmonology, Astana, Kazakhstan.
Patrick NkundanyirazoPartners in Health, Maseru, Lesotho.
Fauziah Asnely PutriInteractive Research and Development Global, Singapore, Singapore.
Charles VilbrunGHESKIO, Port-au-Prince, Haiti.
Munira KhanInteractive Research and Development, Durban, South Africa.
Catherine HewisonMedical Department, Médecins sans Frontières, Paris, France; and.
Palwasha Y KhanDepartment of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Molly F FrankeDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-4890-5728
Funding
Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methodsR01AI146095 · NIAID · HARVARD MEDICAL SCHOOL · PI FRANKE, MOLLY FORREST · 2020 to 2024
$3.6MAbstract
PubMed holds no abstract for this paper.
Indexed as
Antitubercular AgentsTuberculosis, Multidrug-ResistantClofazimineDiarylquinolinesHumansAntitubercular AgentsbedaquilineClofazimineDiarylquinolinesdurationendTB observational studyinverse probability weightingrifampicin-resistant TBtarget trial
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.